Register

Facharzt FMH Medizinische Onkologie Practice Questions - Facharzt FMH Für Medizinische Onkologie Spécialiste FMH En Oncologie Médicale Exam

Access More Questions
A 49-year-old woman with metastatic HER2-positive (IHC 3+) invasive ductal breast cancer experiences disease progression in the liver and lungs while receiving first-line maintenance trastuzumab and pertuzumab following induction docetaxel. She is asymptomatic with an ECOG performance status of 0 and normal baseline left ventricular ejection fraction (LVEF 60%). Based on ESMO guidelines and the DESTINY-Breast03 trial, what is the standard second-line systemic therapy of choice?
Correct Answer:
Trastuzumab deruxtecan (T-DXd)

Access more questions from this quiz

Continue to Facharzt FMH Medizinische Onkologie Practice Questions - Facharzt FMH für Medizinische Onkologie Spécialiste FMH en oncologie médicale Exam for more practice questions and the full quiz experience.

Access More Questions